Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
From our clinical perspective, it's highly unlikely to be a primary driver of weight loss
Future research: TRIUMPH phase 3 program Following the positive results from the NCT 04881760 study, Lilly is planning the TRIUMPH Phase 3 program, which will further test retatrutides impact on chronic weight management, obstructive sleep apnea, and knee osteoarthritis in people with obesity and overweight
BrightMeds launched in December 2023
Compounded medications are typically not covered by insurance plans because they are not FDA-approved branded products
US$ 22.43
US$ 26.18
US$ 26.99
US$ 22.95
